Target discovery opportunities using machine learning on longitudinal patient journeys
Novo Nordisk Research Centre Oxford (NNRCO) is an innovative target discovery and translational research unit with a focus on identifying novel, game-changing therapies for patients with type 2 diabetes and cardio-metabolic diseases. NNRCO employ advanced computational biology, state-of-the-art discovery screening technologies, genetics and human-centric cell systems to dissect pathophysiology and identify novel drug targets.
NNRCO continuously looks for partners with expertise in type 2 diabetes and cardiometabolic diseases, from novel modalities to technologies, in early research to clinical stage. They are interested in academic partners who use disruptive technologies to challenge traditional ways of thinking and benefit unmet patient needs. They offer partners disease understanding, human-centric scientific models, state-of-the-art technologies and tailored collaborations.
7 December 2021, 12:00 (Tuesday, 9th week, Michaelmas 2021)
Dr Ramneek Gupta (Novo Nordisk)
Divisional Office (MSD)
Sheena Lee (MSD Business Partnerships Office),
Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address:
Industry Insight Seminar Series
Members of the University of Oxford and the Biotech/Pharma industry